Symbiotic.blue Launches to Combine Oxford and Cambridge Scientific Brain Power with Bioentrepreneurial Leadership to Reinvent AI Drug Discovery

/EIN News/ -- LONDON, June 19, 2025 (GLOBE NEWSWIRE) -- Symbiotic.blue, the UK’s newest Techbio company has launched to innovate a next-generation artificial intelligence-driven drug discovery (AIDD) platform by combining the power of generative AI with brain-inspired methodologies. Symbiotic.blue aims to create smarter, multi-targeted therapeutics to tackle complex diseases.

Leveraging differentiated multi-modal data, Symbiotic.blue is developing a platform and therapeutic pipeline in parallel, beginning with obesity, in order to prioritise clinical validation.

Founded by a team of world-renowned academics from the Universities of Oxford and Cambridge and seasoned life sciences entrepreneurs, Symbiotic.blue is currently raising a pre-seed round to build its proprietary platform and initiate early-stage discovery programs.

Nigel Brooksby, Symbiotic.blue co-founder and Chairman (and former Chairman & Managing Director of Sanofi) said, “AI and life sciences are priority areas for investment by the UK Government, aimed to turbocharge growth in the economy. By combining the UK’s world-leading strengths in both AI and life sciences, with private capital and Governmental support initiatives, Symbiotic.blue aims to develop a transformative AI-driven drug discovery platform to increase the speed and efficiency and reduce the cost of discovering new therapeutics to address major health challenges.

“Our goal is to build an AI platform that is purposefully different by design, that mimics biology to fast-track the path to novel therapeutics.”

Symbiotic.blue was born from a shared frustration: drug discovery was stuck - too slow, too narrow, and unfit for complex diseases like obesity. Dr. Simon Stringer’s breakthroughs in brain-inspired AI offered a new path - one where machines could model biological nuance, not just process data. Professors Ana Domingos and Gonçalo Bernardes brought deep insights into metabolic biology and chemical design, and the spark turned into a plan. Dr. Kam Pooni joined to translate cutting-edge science into a scalable company, while industry veterans Nigel Brooksby and Rakesh Roshan brought the strategic firepower to make it real. Together, they founded Symbiotic.blue to break the mould and rebuild drug discovery from the ground up - smarter, faster, and biologically aligned.

Dr. Kam Pooni, co-founder and CEO Symbiotic.blue said, “We’re combining the agility of pharmaceutical leadership with the intellectual firepower of top-tier academic minds in AI and drug discovery. We’re not just accelerating discovery; we’re rethinking its foundations from the ground up.”

At the scientific core of Symbiotic.blue are three leading academics:

• Dr. Simon Stringer, Co-founder & Chief AI Officer – Oxford theoretical neuroscientist and pioneer in brain-inspired computational models
• Professor Ana Domingos, Co-founder & Advisor – Oxford expert in obesity and metabolic biology
• Professor Gonçalo Bernardes, Co-founder & Chair of Advisory Board (Drug Development) – Cambridge chemical biologist and global leader in targeted drug design
  

Symbiotic.blue’s platform will integrate two novel technologies: Hierarchical Feature Binding (HFB), in which Dr Stringer has been a key innovator is inspired by how the human brain processes complex information, enabling AI to model biology in a more contextual, layered way. This will be combined with Unimolecular Polypharmacy (UniMP), a technology designed to generate molecules that can simultaneously act on multiple biological targets, increasing potential efficacy and reducing development risk, in which Professor Ana Domingos and Professor Bernardes are experts.

Dr. Simon Stringer, co-founder and Chief AI Officer Symbiotic.blue said, “We’re enhancing Generative AI to build the next generation of drug discovery platforms. By mimicking how the brain binds features hierarchically and combining that with Ana’s expertise in metabolic biology and Gonçalo’s deep understanding of chemical drug design we aim to build a system that can better model biological complexity and help identify multi-target molecules with real therapeutic potential.”

About Symbiotic.blue

Symbiotic.blue, a UK-based Techbio company is innovating a next-generation artificial intelligence-driven drug discovery (AIDD) platform that combines the power of generative AI with brain-inspired methodologies.

The company’s platform will integrate two novel technologies:

• Hierarchical Feature Binding (HFB) - inspired by how the human brain processes complex information, enabling AI to model biology in a more contextual, layered way.
• Unimolecular Polypharmacy (UniMP) - designed to generate molecules that can simultaneously act on multiple biological targets, increasing potential efficacy and reducing development risk.

Symbiotic.blue by founded by leading academics from Oxford and Cambridge Universities, and seasoned life sciences entrepreneurs. It is developing a platform and pipeline in parallel, beginning with obesity, in order to prioritise clinical validation, and is currently raising a pre-seed financing round to build its proprietary platform and initiate early-stage discovery programs.

The company welcomes collaboration from pharmaceutical partners, academic researchers and early-stage investors. To explore opportunities, contact info@symbiotic.blue.

Visit https://symbiotic.blue

Follow us on LinkedIn https://www.linkedin.com/company/symbiotic-blue/about

Media contacts

Sue@charles-consultants.com +44 (0)7968726585

info@symbiotic.blue +44 (0)7462 070088